Genprex Inc Financials

GNPX

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Genprex Inc (GNPX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI GNPX FY2025 2026-05-13

Genprex remains a development-stage company whose cash runway is still created by capital raising rather than self-funded operations.

The biggest change is balance-sheet repair, not operating self-sufficiency: the current ratio moved from 0.8x to 3.8x as financing supplied more cash than the business consumed. Because operating cash flow stayed deeply negative, the stronger liquidity reflects access to outside funding rather than an operating model that now pays for itself.

The latest year’s loss translated into cash burn with little accounting distortion: operating cash outflow was $15.3M versus a net loss of $16.2M. That close match suggests the burn is mostly everyday research and overhead spending, not temporary non-cash charges masking the economics.

The company ended the year with cash of $7.8M against only total liabilities of $2.2M, a much more flexible posture than the prior year’s working-capital squeeze. Spending also still tilts toward R&D over SG&A, which indicates resources remain aimed more at development than commercialization.

Financial Health Signals

Financial Profile 29/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Genprex Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Genprex Inc carries a low D/E ratio of 0.28, meaning only $0.28 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 96/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.84, Genprex Inc holds $3.84 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 75/100.

Returns

Genprex Inc generates a -203.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.

Piotroski F-Score Weak

2/9

Genprex Inc passes 2 of 9 financial strength tests. 1 of 3 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.94x

For every $1 of reported earnings, Genprex Inc generates $0.94 in operating cash flow (-$15.3M OCF vs -$16.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$15.5M

YoY+23.9%

Genprex Inc's EBITDA was -$15.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 23.9% from the prior year.

Net Income

-$16.2M

Genprex Inc reported -$16.2M in net income in fiscal year 2025.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$7.8M

YoY+388.9%

5Y CAGR-22.1%

Genprex Inc held $7.8M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

Genprex Inc had 3M shares outstanding in fiscal year 2025. This represents an increase of 1415.2% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-203.8%

5Y CAGR-145.8pp

Genprex Inc's ROE was -203.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

$9.4M

YoY-10.5%

5Y CAGR+5.2%

Genprex Inc invested $9.4M in research and development in fiscal year 2025. This represents a decrease of 10.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

GNPX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	$0	$0	$0	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$9.4M-10.5%	$10.5M-40.2%	$17.6M+53.1%	$11.5M+28.3%	$9.0M+22.8%	$7.3M
SG&A Expenses	$6.1M-42.7%	$10.6M-20.8%	$13.4M+9.2%	$12.3M+5.3%	$11.7M+9.8%	$10.6M
Operating Income	-$15.5M	N/A	-$31.1M-30.3%	-$23.8M-15.3%	-$20.7M-15.1%	-$18.0M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0-100.0%	$3K	$0	$0	N/A	N/A
Net Income	-$16.2M	N/A	-$30.9M-30.0%	-$23.7M-14.9%	-$20.7M-15.2%	-$17.9M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.7M	N/A	$2.2M-12.3%	$2.5M-1.6%	$2.5M	N/A	$2.8M+65.4%	$1.7M
SG&A Expenses	$1.7M	N/A	$1.2M-47.2%	$2.2M+52.7%	$1.4M	N/A	$1.6M-67.7%	$4.8M
Operating Income	-$4.5M	N/A	-$3.3M+28.5%	-$4.7M-18.0%	-$4.0M	N/A	-$4.3M+33.7%	-$6.5M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$4.5M	N/A	-$3.8M+18.7%	-$4.7M-17.9%	-$4.0M	N/A	-$4.3M+33.6%	-$6.5M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

GNPX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$10.2M+146.3%	$4.1M-61.3%	$10.7M-57.5%	$25.1M-41.5%	$42.9M+36.6%	$31.4M
Current Assets	$8.4M+302.3%	$2.1M-72.4%	$7.5M-64.9%	$21.5M-45.1%	$39.1M+41.3%	$27.7M
Cash & Equivalents	$7.8M+388.9%	$1.6M-76.2%	$6.7M-67.8%	$21.0M-45.8%	$38.6M+41.4%	$27.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	$0-100.0%	$35K	$0-100.0%	$127
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.2M-12.3%	$2.5M-23.0%	$3.3M+15.8%	$2.8M+77.3%	$1.6M+251.7%	$451K
Current Liabilities	$2.2M-13.2%	$2.5M-23.0%	$3.3M+15.8%	$2.8M+77.3%	$1.6M+251.7%	$451K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$8.0M+391.4%	$1.6M-78.2%	$7.4M-66.7%	$22.3M-46.0%	$41.3M+33.5%	$30.9M
Retained Earnings	-$171.0M-10.5%	-$154.8M-15.8%	-$133.7M-30.0%	-$102.8M-30.0%	-$79.1M-35.4%	-$58.4M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$20.3M+99.9%	$10.2M+185.2%	$3.6M-6.9%	$3.8M-36.3%	$6.0M+45.7%	$4.1M+5.6%	$3.9M-40.8%	$6.6M
Current Assets	$18.8M+125.0%	$8.4M+387.2%	$1.7M-16.6%	$2.1M-50.6%	$4.2M+100.4%	$2.1M+8.3%	$1.9M-56.4%	$4.4M
Cash & Equivalents	$18.0M+130.5%	$7.8M+609.8%	$1.1M-18.1%	$1.3M-61.2%	$3.5M+116.5%	$1.6M+7.6%	$1.5M-39.5%	$2.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.4M+53.7%	$2.2M-21.4%	$2.8M+14.7%	$2.4M+13.7%	$2.1M-14.5%	$2.5M+11.7%	$2.2M-0.8%	$2.3M
Current Liabilities	$3.4M+54.2%	$2.2M-14.8%	$2.6M+4.7%	$2.4M+13.7%	$2.1M-14.5%	$2.5M+11.7%	$2.2M-0.8%	$2.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$16.9M+112.6%	$8.0M+937.0%	$768K-44.8%	$1.4M-64.0%	$3.9M+138.7%	$1.6M-2.7%	$1.7M-61.7%	$4.3M
Retained Earnings	-$175.5M-2.6%	-$171.0M-2.3%	-$167.2M-2.3%	-$163.4M-2.9%	-$158.8M-2.6%	-$154.8M-2.9%	-$150.5M-3.0%	-$146.2M

GNPX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$15.3M+14.6%	-$17.9M+27.6%	-$24.7M-40.4%	-$17.6M-23.4%	-$14.3M-2.5%	-$13.9M
Capital Expenditures	N/A	N/A	N/A	$0-100.0%	$32K+80.5%	$18K
Free Cash Flow	N/A	N/A	N/A	-$17.6M-23.1%	-$14.3M-2.6%	-$14.0M
Investing Cash Flow	$0-100.0%	$775K+1187.8%	-$71K-19.2%	-$60K+28.7%	-$84K+96.4%	-$2.3M
Financing Cash Flow	$21.5M+79.3%	$12.0M+13.4%	$10.6M+164751.8%	$6K-100.0%	$25.7M-38.3%	$41.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$3.1M+23.4%	-$4.1M-28.6%	-$3.2M+17.5%	-$3.9M+7.1%	-$4.2M-7.5%	-$3.9M-77.0%	-$2.2M+66.7%	-$6.6M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	$0	$0	$0	$0+100.0%	-$1	$0-100.0%	$790K
Financing Cash Flow	$13.4M+23.4%	$10.8M+267.8%	$2.9M+68.9%	$1.7M-71.1%	$6.0M+51.4%	$4.0M+227.8%	$1.2M+5752.9%	$21K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

GNPX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-203.8%	N/A	-416.1%-309.5pp	-106.6%-56.5pp	-50.1%+8.0pp	-58.0%
Return on Assets	-159.8%	N/A	-289.2%-194.6pp	-94.6%-46.4pp	-48.2%+9.0pp	-57.2%
Current Ratio	3.84+3.0	0.83-1.5	2.31-5.3	7.64-17.0	24.69-36.8	61.47
Debt-to-Equity	0.28-1.3	1.55+1.1	0.44+0.3	0.13+0.1	0.04+0.0	0.01
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-26.4%	N/A	-494.8%-158.8pp	-336.0%-233.5pp	-102.5%	N/A	-259.2%-109.7pp	-149.5%
Return on Assets	-22.0%	N/A	-106.6%+15.5pp	-122.1%-56.2pp	-66.0%	N/A	-110.5%-12.1pp	-98.4%
Current Ratio	5.61+1.8	3.84+3.2	0.67-0.2	0.84-1.1	1.94+1.1	0.83-0.0	0.86-1.1	1.95
Debt-to-Equity	0.20-0.1	0.28-3.4	3.64+1.9	1.75+1.2	0.55-1.0	1.55+0.2	1.35+0.8	0.52
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

In8Bio, Inc. INAB

$16.5M

KIORA PHARMACEUTICALS INC KPRX

$11.9M

Creative Med Technology Hldgs CELZ

$8.5M

Calidi Biotherapeutics Inc CLDI

$3.7M

Transcode Therapeutics Inc RNAZ

$5.8M

Frequently Asked Questions

Is Genprex Inc profitable?

No, Genprex Inc (GNPX) reported a net income of -$16.2M in fiscal year 2025.

What is Genprex Inc's EBITDA?

Genprex Inc (GNPX) had EBITDA of -$15.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Genprex Inc's return on equity (ROE)?

Genprex Inc (GNPX) has a return on equity of -203.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Genprex Inc's operating cash flow?

Genprex Inc (GNPX) generated -$15.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Genprex Inc's total assets?

Genprex Inc (GNPX) had $10.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Genprex Inc spend on research and development?

Genprex Inc (GNPX) invested $9.4M in research and development during fiscal year 2025.

How many shares does Genprex Inc have outstanding?

Genprex Inc (GNPX) had 3M shares outstanding as of fiscal year 2025.

What is Genprex Inc's current ratio?

Genprex Inc (GNPX) had a current ratio of 3.84 as of fiscal year 2025, which is generally considered healthy.

What is Genprex Inc's debt-to-equity ratio?

Genprex Inc (GNPX) had a debt-to-equity ratio of 0.28 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Genprex Inc's return on assets (ROA)?

Genprex Inc (GNPX) had a return on assets of -159.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Genprex Inc's cash runway?

Based on fiscal year 2025 data, Genprex Inc (GNPX) had $7.8M in cash against an annual operating cash burn of $15.3M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Genprex Inc's Piotroski F-Score?

Genprex Inc (GNPX) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Genprex Inc's earnings high quality?

Genprex Inc (GNPX) has an earnings quality ratio of 0.94x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Genprex Inc?

Genprex Inc (GNPX) scores 29 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.